तुलना करने के लिए मीट्रिक्स | TRVN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधTRVNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 0.0x | −5.7x | −0.2x | |
PEG अनुपात | 0.00 | −0.11 | 0.00 | |
क़ीमत/बुक | 0.0x | 0.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 5.6x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 158.5% | 65.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.0% | 10.0% | अनलॉक करें |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.